NIKKEI 225
38,259.46 -14.59 (-0.04%) HANG SENG
18,183.59 +420.56 (+2.37%) CRUDE OIL
79.47 +0.47 (+0.59%) GOLD FUTURES
2,324.10 +13.10 (+0.57%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,776.73 -2,020.43 (-4.23%)
Dr. Reddy's Laboratories Limited (DRREDDY.NS)
- GlobeNewswire
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
- Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
- Zacks
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
